C07K 14/57509
Corticotropin releasing factor [crf]
Official title: {Corticotropin releasing factor [CRF] (Urotensin)}
C07K14/57509 (Corticotropin releasing factor [crf]) appears on 86 US grants and 85 published applications in this corpus.
Search patents in C07K- Granted patents
- 86
- Published applications
- 85
- Assignees
- 44
- Inventors
- 188
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 0 |
| 2002 | 1 | 4 |
| 2003 | 0 | 8 |
| 2004 | 1 | 7 |
| 2005 | 6 | 5 |
| 2006 | 1 | 3 |
| 2007 | 7 | 2 |
| 2008 | 2 | 6 |
| 2009 | 5 | 5 |
| 2010 | 2 | 4 |
| 2011 | 5 | 3 |
| 2012 | 0 | 4 |
| 2013 | 3 | 1 |
| 2014 | 1 | 4 |
| 2015 | 1 | 4 |
| 2016 | 2 | 5 |
| 2017 | 1 | 1 |
| 2018 | 1 | 4 |
| 2019 | 2 | 4 |
| 2020 | 0 | 0 |
| 2021 | 3 | 3 |
| 2022 | 1 | 1 |
| 2023 | 1 | 1 |
| 2024 | 1 | 2 |
| 2025 | 3 | 4 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CRF2 receptor agonists and their use in therapy14 Jul 2026US 12,679,878 B2Sanofi
- Amino diacids containing peptide modifiers14 Oct 2025US 12,441,760 B2Chemical & Biopharmaceutical Laboratories of Patras S.A.
- Dietary peptides13 May 2025US 12,295,397 B2Diet4Life APS
- Materials and methods for treating stress-related disorders and cancer25 Mar 2025US 12,258,395 B2University of Florida Research Foundation, Inc.
- Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes24 Sep 2024US 12,098,179 B2Centre National de la Recherche Scientifique (CNRS)
- Crf2 receptor agonists and their use in therapy31 Jul 2025US 2025/0243255 A1Sanofi
- Materials and methods for treating stress-related disorders and cancer5 Jun 2025US 2025/0179168 A1University of Florida Research Foundation, Inc.
- Compounds for the treatment of diabetes or obesity22 May 2025US 2025/0163119 A1Eli Lilly and Company
- Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes13 Mar 2025US 2025/0084143 A1Centre National de la Recherche Scientifique (CNRS)
- Compositions and Methods of Treatment Using CRRL 19111 Apr 2024US 2024/0116990 A1Mayo Foundation for Medical Education and Research
Most cited
By later US patents
- Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties153US 5,362,852 APfizer Inc. · 1994
- CRF antagonists74US 4,605,642 AThe Salk Institute for Biological Studies · 1986
- CRF antagonists34US 5,245,009 AThe Salk Institute for Biological Studies · 1993
- CRF And analogs29US 4,415,558 AThe Salk Institute for Biological Studies · 1983
- Heregulin variants27US 6,136,558 AGenentech, Inc. · 2000